- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 231/14
Total number of patents in this class: 1171
10-year publication summary
|
71
|
93
|
79
|
71
|
76
|
79
|
66
|
54
|
47
|
21
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bayer Cropscience AG | 1885 |
60 |
| Theravance Biopharma R&D IP, LLC | 425 |
48 |
| Syngenta Participations AG | 1581 |
38 |
| BASF SE | 21150 |
36 |
| BioCryst Pharmaceuticals, Inc. | 179 |
31 |
| Syngenta Crop Protection AG | 6513 |
28 |
| Orion Corporation | 750 |
19 |
| Takeda Pharmaceutical Company Limited | 2718 |
18 |
| Sumitomo Chemical Company, Limited | 9055 |
15 |
| Activesite Pharmaceuticals, Inc. | 18 |
15 |
| Syngenta Limited | 436 |
14 |
| AstraZeneca AB | 2832 |
12 |
| Solvay SA | 958 |
12 |
| Dow AgroSciences LLC | 1196 |
11 |
| sanofi-aventis | 327 |
11 |
| F. Hoffmann-La Roche AG | 7837 |
10 |
| Hoffmann-La Roche Inc. | 3699 |
10 |
| Bayer Intellectual Property GmbH | 2405 |
10 |
| Loxo Oncology, Inc. | 82 |
10 |
| Research Triangle Institute | 415 |
10 |
| Other owners | 753 |